Ezra E.W. Cohen, MD of University of California, San Diego explains how biomarkers and combination therapy may be the path ahead for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Biomarkers & Combination Therapy May Be the Path Ahead for Immunotherapy
